Form 4: Emergent BioSolutions SVP William Hartzel Reports Acquisition of Stock and Options

William Hartzel, SVP of Bioservices at Emergent BioSolutions, reports acquiring 62,500 shares of common stock and 62,500 employee stock options.

Summary

• William Hartzel, SVP of Bioservices at Emergent BioSolutions Inc., filed a Form 4 on March 10, 2025.
• The report details transactions from March 6, 2025, including the acquisition of 62,500 shares of common stock and 62,500 employee stock options.
• The common stock was acquired through restricted stock units granted under the company's Stock Incentive Plan.
• These restricted stock units vest in three annual installments beginning on the day prior to the anniversary of the date of grant, assuming continued service.
• Each restricted stock unit represents the right to receive one share of common stock.
• The employee stock options have an exercise price of $5.80 and also vest in three equal installments beginning on the day prior to the anniversary date of the grant, expiring on March 5, 2032.
• Following the reported transactions, Hartzel beneficially owns 109,975 shares of common stock and 214,711 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock and option grants to an executive. It doesn't inherently indicate positive or negative performance, but rather a routine part of executive compensation.

Positives

• The acquisition of stock and options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The restricted stock units vest in three annual installments, assuming continued service with the company. The employee stock options also vest in three equal installments.

Industry Context

Form 4 filings are a routine part of regulatory compliance for company insiders and provide transparency into their transactions in the company's securities.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
• The vesting schedules for these equity grants are typical, usually spanning several years to incentivize long-term commitment.

Stakeholder Impact

• The transactions reported may have a minor impact on shareholders by potentially diluting the stock if the options are exercised and the restricted stock units vest.

Key Dates